Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables (2016 - 2025)

Historic Receivables for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $250.5 million.

  • Coherus Oncology's Receivables rose 2600.4% to $250.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.5 million, marking a year-over-year increase of 2600.4%. This contributed to the annual value of $122.3 million for FY2024, which is 5304.27% down from last year.
  • Latest data reveals that Coherus Oncology reported Receivables of $250.5 million as of Q3 2025, which was up 2600.4% from $119.6 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Receivables ranged from a high of $313.6 million in Q2 2024 and a low of $62.4 million during Q1 2025
  • Its 5-year average for Receivables is $160.4 million, with a median of $136.3 million in 2021.
  • In the last 5 years, Coherus Oncology's Receivables skyrocketed by 18006.76% in 2024 and then crashed by 7802.72% in 2025.
  • Coherus Oncology's Receivables (Quarter) stood at $123.0 million in 2021, then decreased by 10.61% to $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then tumbled by 53.04% to $122.3 million in 2024, then surged by 104.76% to $250.5 million in 2025.
  • Its last three reported values are $250.5 million in Q3 2025, $119.6 million for Q2 2025, and $62.4 million during Q1 2025.